Your browser doesn't support javascript.
loading
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok, Jeongha; Lee, Myungsun; Kim, Deog Kyeom; Kim, Ju Sang; Jhun, Byung Woo; Jo, Kyung-Wook; Jeon, Doosoo; Lee, Taehoon; Lee, Ji Yeon; Park, Jae Seuk; Lee, Seung Heon; Kang, Young Ae; Lee, Jung-Kyu; Kwak, Nakwon; Ahn, Joong Hyun; Shim, Tae Sun; Kim, Song Yee; Kim, Seungmo; Kim, Kyungjong; Seok, Kwang-Hyuk; Yoon, Soyeong; Kim, Young Ran; Kim, Jisu; Yim, Dahae; Hahn, Seokyung; Cho, Sang Nae; Yim, Jae-Joon.
Afiliación
  • Mok J; Division of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea.
  • Lee M; Division of Clinical Research, International Tuberculosis Research Centre, Seoul, South Korea.
  • Kim DK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Centre, Seoul, South Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Kim JS; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Jhun BW; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Jo KW; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Jeon D; Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea.
  • Lee T; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
  • Lee JY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Centre, Seoul, South Korea.
  • Park JS; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dankook University Hospital, Cheonan, South Korea.
  • Lee SH; Department of Pulmonology, Korea University Ansan Hospital, Ansan, South Korea.
  • Kang YA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Lee JK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Centre, Seoul, South Korea.
  • Kwak N; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Ahn JH; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Shim TS; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Kim SY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim S; Department of Laboratory Medicine, The Korean Institute of Tuberculosis, Cheongju, South Korea.
  • Kim K; Department of R&D, The Korean Institute of Tuberculosis, Cheongju, South Korea; DNA Analysis Division, Seoul Institute, National Forensic Service, Seoul, South Korea.
  • Seok KH; Department of Laboratory Medicine, The Korean Institute of Tuberculosis, Cheongju, South Korea.
  • Yoon S; Division of Clinical Research, International Tuberculosis Research Centre, Seoul, South Korea.
  • Kim YR; Division of Clinical Research, International Tuberculosis Research Centre, Seoul, South Korea.
  • Kim J; Medical Research Collaborating Centre, Seoul National University Hospital, Seoul, South Korea.
  • Yim D; Medical Research Collaborating Centre, Seoul National University Hospital, Seoul, South Korea.
  • Hahn S; Department of Human Systems Medicine, Seoul National University College of Medicine, Seoul, South Korea; Medical Research Collaborating Centre, Seoul National University Hospital, Seoul, South Korea.
  • Cho SN; Division of Clinical Research, International Tuberculosis Research Centre, Seoul, South Korea.
  • Yim JJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: yimjj@snu.ac.kr.
Lancet ; 400(10362): 1522-1530, 2022 10 29.
Article en En | MEDLINE | ID: mdl-36522208
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazinamida / Tuberculosis Resistente a Múltiples Medicamentos Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Lancet Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazinamida / Tuberculosis Resistente a Múltiples Medicamentos Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Lancet Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur